MA
Agent Service · x402 · early usage
Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzum…
Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Conc…
by api.magentlab.com · discovered, not yet claimed by its owner · updated 2026-10-12
30d calls3
30d payers1
MethodPOST
Outputjson
Mirrored from Coinbase's public x402 Bazaar. The description is the provider's own text and has not been reviewed here; the payment requirements are copied as published.
What it does
Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.
Tags: hfa-icos · her2 · cardio-oncology · trastuzumab · calculator · bazaar
Call contract
- Method
- POST
- Input
- HTTP request
- Output
- json
- Last paid call
- 2026-10-12
Input example from Bazaar metadata
{
"items": [
{
"age_years": 50,
"anthracycline_before_her2": false,
"arrhythmia": false,
"ckd": false,
"concurrent_anthracycline_and_her2": false,
"current_or_significant_smoker": false,
"diabetes": false,
"elevated_bnp": false,
"elevated_troponin": false,
"heart_failure_or_cardiomyopathy": false,
"hypertension": false,
"lvef_percent": 60,
"mi_or_cabg": false,
"obesity": false,
"prior_left_chest_or_mediastinal_rt": false,
"prior_remote_anthracycline": false,
"prior_trastuzumab_cardiotoxicity": false,
"severe_valvular_heart_disease": false,
"stable_angina": false
},
{
"age_years": 50,
"anthracycline_before_her2": false,
"arrhythmia": false,
"ckd": false,
"concurrent_anthracycline_and_her2": false,
"current_or_significant_smoker": false,
"diabetes": false,
"elevated_bnp": false,
"elevated_troponin": false,
"heart_failure_or_cardiomyopathy": false,
"hypertension": false,
"lvef_percent": 60,
"mi_or_cabg": false,
"obesity": false,
"prior_left_chest_or_mediastinal_rt": false,
"prior_remote_anthracycline": false,
"prior_trastuzumab_cardiotoxicity": false,
"severe_valvular_heart_disease": false,
"stable_angina": false
}
]
}Output example
{
"count": 2,
"items": [
{
"age_years": 50,
"anthracycline_before_her2": false,
"cardiotoxicity_guide": "<2%",
"citation": {
"authors": "Lyon AR, Dent S, Stanway S, et al.",
"doi": "10.1002/ejhf.1920",
"id": "lyon-2020",
"pmid": "32458582",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
},
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false
},
{
"factor": "prior_trastuzumab_cardiotoxicity",
"points": 0,
"present": false
},
{
"factor": "mi_or_cabg",
"points": 0,
"present": false
},
{
"factor": "stable_angina",
"points": 0,
"present": false
},
{
"factor": "severe_valvular_heart_disease",
"points": 0,
"present": false
},
{
"factor": "lvef_lt_50",
"points": 0,
"present": false,
"value": 60
},
{
"factor": "age_ge_80",
"points": 0,
"present": false,
"value": 50
},
{
"factor": "concurrent_anthracycline_and_her2",
"points": 0,
"present": false
},
{
"factor": "lvef_50_54",
"points": 0,
"present": false,
"value": 60
},
{
"factor": "arrhythmia",
"points": 0,
"present": false
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false
},
{
"factor": "age_65_79",
"points": 0,
"present": false,
"value": 50
},
{
"factor": "prior_remote_anthracycline",
"points": 0,
"present": false
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false
},
{
"factor": "hypertension",
"points": 0,
"present": false
},
{
"factor": "diabetes",
"points": 0,
"present": false
},
{
"factor": "ckd",
"points": 0,
"present": false
},
{
"factor": "anthracycline_before_her2",
"points": 0,
"present": false
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false
},
{
"factor": "obesity",
"points": 0,
"present": false
}
],
"concurrent_anthracycline_and_her2": false,
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"formula": "hfa_icos_her2",
"formula_expression": "HFA-ICOS HER2 (Lyon 2020): very_high if heart_failure_or_cardiomyopathy or prior_trastuzumab_cardiotoxicity; else high if mi_or_cabg or stable_angina or severe_valvular_heart_disease or lvef_percent<50 or age_years>=80 or concurrent_anthracycline_and_her2 or medium_points>=5; else medium if medium_points 2-4; else low; medium_points = Medium 2 (2) + Medium 1 (1); Medium 2 = lvef 50-54, arrhythmia, elevated_troponin, elevated_bnp, age 65-79, prior_remote_anthracycline, prior_left_chest_or_mediastinal_rt; Medium 1 = hypertension, diabetes, ckd, anthracycline_before_her2 (if not concurrent), current_or_significant_smoker, obesity; cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"high_present": false,
"lvef_percent": 60,
"max_score": 20,
"medium_points": 0,
"risk_level": "low",
"score": 0,
"very_high_present": false
},
{
"age_years": 50,
"anthracycline_before_her2": false,
"cardiotoxicity_guide": "<2%",
"citation": {
"authors": "Lyon AR, Dent S, Stanway S, et al.",
"doi": "10.1002/ejhf.1920",
"id": "lyon-2020",
"pmid": "32458582",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
},
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false
},
{
"factor": "prior_trastuzumab_cardiotoxicity",
"points": 0,
"present": false
},
{
"factor": "mi_or_cabg",
"points": 0,
"present": false
},
{
"factor": "stable_angina",
"points": 0,
"present": false
},
{
"factor": "severe_valvular_heart_disease",
"points": 0,
"present": false
},
{
"factor": "lvef_lt_50",
"points": 0,
"present": false,
"value": 60
},
{
"factor": "age_ge_80",
"points": 0,
"present": false,
"value": 50
},
{
"factor": "concurrent_anthracycline_and_her2",
"points": 0,
"present": false
},
{
"factor": "lvef_50_54",
"points": 0,
"present": false,
"value": 60
},
{
"factor": "arrhythmia",
"points": 0,
"present": false
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false
},
{
"factor": "age_65_79",
"points": 0,
"present": false,
"value": 50
},
{
"factor": "prior_remote_anthracycline",
"points": 0,
"present": false
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false
},
{
"factor": "hypertension",
"points": 0,
"present": false
},
{
"factor": "diabetes",
"points": 0,
"present": false
},
{
"factor": "ckd",
"points": 0,
"present": false
},
{
"factor": "anthracycline_before_her2",
"points": 0,
"present": false
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false
},
{
"factor": "obesity",
"points": 0,
"present": false
}
],
"concurrent_anthracycline_and_her2": false,
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"formula": "hfa_icos_her2",
"formula_expression": "HFA-ICOS HER2 (Lyon 2020): very_high if heart_failure_or_cardiomyopathy or prior_trastuzumab_cardiotoxicity; else high if mi_or_cabg or stable_angina or severe_valvular_heart_disease or lvef_percent<50 or age_years>=80 or concurrent_anthracycline_and_her2 or medium_points>=5; else medium if medium_points 2-4; else low; medium_points = Medium 2 (2) + Medium 1 (1); Medium 2 = lvef 50-54, arrhythmia, elevated_troponin, elevated_bnp, age 65-79, prior_remote_anthracycline, prior_left_chest_or_mediastinal_rt; Medium 1 = hypertension, diabetes, ckd, anthracycline_before_her2 (if not concurrent), current_or_significant_smoker, obesity; cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"high_present": false,
"lvef_percent": 60,
"max_score": 20,
"medium_points": 0,
"risk_level": "low",
"score": 0,
"very_high_present": false
}
],
"path": "/api/calc/hfa_icos_her2"
}Use with an agent
- Discover. Agents find this listing with
GET https://bazaar.saylorinnovations.com/discovery/search?query=…, the MCP toolsearch_resources, or/discovery/resources. - Inspect. Fetch
/resources/39590.jsonfor the price and payment options. - Pay. Call
GET https://api.magentlab.com/api/calc/hfa_icos_her2. The provider answers402with its payment requirements. An x402 client signs one of the options below and retries withPAYMENT-SIGNATURE. - Execute. The provider returns
200with the data. Agent Bazaar is not in the request path and never sees your payment.
For humans
You don't need an account or an API key; you need a wallet holding a small amount of USDC on Base, and an x402-capable client (see the examples below). Call the endpoint unpaid first to see exactly what it asks for.
Pricing & payment
- Price
- $0.005 / request
- Protocol
- x402 v2
- Auth
- No account or API key. Pay per request.
- Networks
- Base
- Demand
- 3 calls · 1 unique payers in 30d (public x402 Bazaar data)
x402 payment requirements
| Scheme | Network | Asset | Amount | Pay to | Timeout |
|---|---|---|---|---|---|
| exact | Base eip155:8453 | USDC | $0.005 | 0x836Be278f1739fB4308091cD1852F7971Bc19Ee2 | 600s |
accepts[] (raw JSON)
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "5000",
"amountUsd": 0.005,
"maxTimeoutSeconds": 600
}
]Schemas
Output schema (JSON Schema)
{
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}Example shape — generated from the schema, not a captured live response
{
"example": {},
"type": "string"
}Examples
curl
curl "https://api.magentlab.com/api/calc/hfa_icos_her2"
# -> 402 Payment Required, accepts[] lists how to pay
# retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paidJavaScript
const res = await fetch("https://api.magentlab.com/api/calc/hfa_icos_her2");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://api.magentlab.com/api/calc/hfa_icos_her2")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerDetails
- Provider
- api.magentlab.com
- Endpoint
- https://api.magentlab.com/api/calc/hfa_icos_her2
- Machine-readable
/resources/39590.json